title: Prevention of LPS-induced microglia activation, cytokine production and sickness behavior with TLR4 receptor interfering peptides.
abstract: The innate immune receptor Toll-like 4 (TLR4) is the receptor activated by lipopolysaccharide (LPS), and TLR4-LPS interaction is well known to induce an innate immune response, triggering sickness behavior. Within the brain, TLR4 is highly expressed in brain microglia, and excessive inflammation resulting from activation of this pathway in the brain has been implicated in depressive disorders and neurodegenerative pathologies. We hypothesized that blocking LPS-induced activation of TLR4 would prevent downstream immune signaling in the brain and suppress the induction of sickness behavior. We used interfering peptides to block TLR4 activation and confirmed their efficacy in preventing second messenger activation and cytokine production normally induced by LPS treatment. Further, these peptides blocked morphological changes in microglia that are typically induced by LPS. We also demonstrated that intraperitoneal (i.p.) injection of Tat-TLR4 interfering peptides prevented LPS-induced sickness behavior, as assessed in home cage behavior and with the intracranial self-stimulation paradigm. These newly synthesised peptides inhibit TLR4 signaling thereby preventing changes in behavior and motivation caused by inflammatory stimuli. These peptides highlight the roll of TLR4 and microglia morphology changes in sickness behavior, and thus may be of therapeutic value in limiting the deleterious impact of excessive inflammation in specific CNS pathologies.
authors.affiliation: Department of Psychiatry and Brain Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Dustin J
authors.initials: DJ
authors.lastname: Hines
authors.forename: Hyun B
authors.initials: HB
authors.lastname: Choi
authors.forename: Rochelle M
authors.initials: RM
authors.lastname: Hines
authors.forename: Anthony G
authors.initials: AG
authors.lastname: Phillips
authors.forename: Brian A
authors.initials: BA
authors.lastname: MacVicar
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D016207:Cytokines / Q000276:immunology*; D006801:Humans; D055809:Illness Behavior / Q000187:drug effects*; D007113:Immunity, Innate / Q000187:drug effects; D008070:Lipopolysaccharides / Q000276:immunology*; D051379:Mice; D017628:Microglia / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008969:Molecular Sequence Data; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D051197:Toll-Like Receptor 4 / Q000037:antagonists & inhibitors* / Q000276:immunology*
chemical_list: D016207:Cytokines; D008070:Lipopolysaccharides; D010455:Peptides; D051197:Toll-Like Receptor 4
references.citation: Neurochem Int. 1996 Jul;29(1):25-35
references.pmid: 8808786
references.citation: Brain Behav Immun. 2003 Feb;17 Suppl 1:S112-8
references.pmid: 12615196
references.citation: J Leukoc Biol. 2007 Oct;82(4):801-10
references.pmid: 17548806
references.citation: Nat Rev Neurosci. 2008 Jan;9(1):46-56
references.pmid: 18073775
references.citation: FASEB J. 2001 Jan;15(1):155-163
references.pmid: 11149903
references.citation: Nat Genet. 2005 Nov;37(11):1155
references.pmid: 16254554
references.citation: Nat Neurosci. 2007 Nov;10(11):1387-94
references.pmid: 17965659
references.citation: Ann N Y Acad Sci. 2001 Mar;933:222-34
references.pmid: 12000023
references.citation: Trends Neurosci. 2002 Nov;25(11):546-7
references.pmid: 12392922
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8514-9
references.pmid: 12824464
references.citation: Trends Neurosci. 2002 Mar;25(3):154-9
references.pmid: 11852148
references.citation: Brain Res Bull. 1984 Feb;12(2):195-201
references.pmid: 6609750
references.citation: Immunol Rev. 2000 Feb;173:89-97
references.pmid: 10719670
references.citation: Nature. 2004 Sep 9;431(7005):195-9
references.pmid: 15356633
references.citation: J Biol Chem. 2005 Apr 22;280(16):15809-14
references.pmid: 15755740
references.citation: J Neurosci. 2005 Feb 16;25(7):1788-96
references.pmid: 15716415
references.citation: Biochem Pharmacol. 2006 Oct 30;72(9):1102-13
references.pmid: 16930560
references.citation: Brain Behav Immun. 2004 Sep;18(5):407-13
references.pmid: 15265532
references.citation: Eur J Neurosci. 2008 Dec;28(12):2499-510
references.pmid: 19087175
references.citation: Glia. 2001 Mar 1;33(3):256-66
references.pmid: 11241743
references.citation: Neurosci Biobehav Rev. 1988 Summer;12(2):123-37
references.pmid: 3050629
references.citation: Int J Neuropsychopharmacol. 2003 Mar;6(1):23-34
references.pmid: 12899733
references.citation: Neuroreport. 1998 Dec 1;9(17):3797-802
references.pmid: 9875707
references.citation: Nature. 2007 Apr 26;446(7139):987-9
references.pmid: 17410127
references.citation: Nat Rev Neurosci. 2001 Oct;2(10):734-44
references.pmid: 11584311
references.citation: EMBO J. 1991 Jul;10(7):1733-9
references.pmid: 2050110
references.citation: Mol Cell Biol. 2000 Jun;20(11):4106-14
references.pmid: 10805752
references.citation: Mol Vis. 2006 May 10;12:467-77
references.pmid: 16710171
references.citation: Science. 1998 Dec 11;282(5396):2085-8
references.pmid: 9851930
references.citation: Mol Psychiatry. 2008 May;13(5):480-97
references.pmid: 18180766
references.citation: Glia. 2009 Nov 15;57(15):1610-8
references.pmid: 19382211
references.citation: Science. 2005 May 27;308(5726):1314-8
references.pmid: 15831717
references.citation: PLoS Genet. 2006 Aug 25;2(8):e118
references.pmid: 16933996